Pomerantz Law Firm Notifies Humacyte Investors About Class Action Lawsuit and Important Dates

Shareholder Alert: Important News for Humacyte Investors

Pomerantz LLP, a leading law firm recognized for its expertise in corporate and securities litigation, has announced the initiation of a class action lawsuit against Humacyte, Inc. (NASDAQ: HUMA). The firm is urging investors who have incurred losses on their investments in Humacyte to come forward and participate in the legal proceedings. This article outlines the details surrounding the lawsuit, the allegations against Humacyte, and key dates for shareholders.

Allegations Against Humacyte

The class action primarily concerns allegations of securities fraud and other unlawful business practices by Humacyte and several of its key executives. Investors who acquired Humacyte securities during the specified class period could be eligible to join the lawsuit. Individuals interested in becoming lead plaintiffs are encouraged to contact Pomerantz LLP, providing their contact information and details of their stock purchases.

Background of Events

In a press release dated August 9, 2024, Humacyte informed the public that the U.S. Food and Drug Administration (FDA) would require more time to complete its review of the company’s Biologic License Application (BLA) for their acellular tissue engineered vessel (ATEV) intended for vascular trauma treatment. This announcement caused Humacyte's stock price to plunge by $1.30 per share, marking a significant decline of 16.43%, when it closed at $6.61 on August 12, 2024.

Following this, on October 17, 2024, the FDA issued a Form 483 citing several compliance issues at Humacyte's Durham, North Carolina facility, including serious violations related to quality assurance and oversight. Consequently, Humacyte's share price fell by an additional $0.95, closing at $4.86, reflecting a 16.35% decrease on the day of the FDA's findings.

Important Dates for Shareholders

Investors must act swiftly. The deadline for shareholders to seek appointment as a Lead Plaintiff in the class action lawsuit is January 17, 2025. Interested parties should refer to the Pomerantz website for access to the complaint and further information on joining the class action.

About Pomerantz LLP

Founded over 85 years ago by the late Abraham L. Pomerantz, widely recognized as the dean of the class action bar, Pomerantz LLP has established itself as a formidable entity in the realm of securities litigation. The firm has a significant history of pursuing justice for victims of securities fraud, recovering billions of dollars for its clients over the years.

For those who believe they may qualify for this class action, Pomerantz invites them to reach out to Danielle Peyton at the firm. They can contact her via email at [email protected] or at 646-581-9980, with specific extension 7980. When communicating via email, investors are encouraged to include their mailing address and phone number for convenience.

Conclusion

As the deadline approaches, it is crucial for investors affected by Humacyte’s recent announcements and stock performance to take appropriate action. Pomerantz LLP’s alert emphasizes the significance of the class action lawsuit and provides a compelling opportunity for involved shareholders to reclaim their investments.

For further updates and detailed information, visit the Pomerantz LLP website.